**Supplementary Table 1: Results per country and scenario: Life years, Quality Adjusted Life Years, Costs and Incremental Cost-effectiveness Ratios (discount rate 5%, 2012 USD).**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Argentina** | | | **Bolivia** | | | **Brazil** | | | **Chile** | | | **Colombia** | | | **Peru** | | | **Uruguay** | | |
|  | NT | Tzb | Diff | NT | Tzb | Diff | NT | Tzb | Diff | NT | Tzb | Diff | NT | Tzb | Diff | NT | Tzb | Diff | NT | Tzb | Diff |
| **Base case** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LYs | 10∙07 | 11∙03 | 0∙97 | 9∙42 | 10∙29 | 0∙87 | 9∙77 | 10∙69 | 0∙92 | 10∙24 | 11∙24 | 1∙00 | 10∙04 | 11∙01 | 0∙96 | 9∙83 | 10∙77 | 0∙93 | 10∙10 | 11∙07 | 0∙97 |
| QALYs | 8∙12 | 8∙70 | 0∙58 | 7∙59 | 8∙11 | 0∙51 | 7∙88 | 8∙43 | 0∙55 | 8∙26 | 8∙86 | 0∙60 | 8∙10 | 8∙68 | 0∙58 | 7∙93 | 8∙49 | 0∙56 | 8∙15 | 8∙73 | 0∙59 |
| Costs\* | 12∙21 | 57∙21 | 45∙00 | 20∙11 | 56∙24 | 36∙13 | 9∙09 | 69∙92 | 60∙83 | 16∙63 | 50∙20 | 33∙57 | 71∙55 | 117∙23 | 45∙68 | 21∙00 | 52∙17 | 31∙17 | 14∙92 | 39∙61 | 24∙68 |
| ICER x USD (x GDPpc) | **77,273 (8∙47)** | | | **70,202 (35∙47)** | | | **110,283 (10∙30)** | | | **55,928 (4∙50)** | | | **78,946 (12∙65)** | | | **55,821 (10∙34)** | | | **42,104 (3∙62)** | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Scenario 2** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LYs | 9∙09 | 10∙17 | 1∙08 | 7∙87 | 8∙92 | 1∙06 | 8∙40 | 9∙48 | 1∙08 | 8∙63 | 9∙80 | 1∙16 | 6∙86 | 8∙11 | 1∙26 | 8∙80 | 9∙86 | 1∙05 | 7∙19 | 8∙44 | 1∙25 |
| QALYs | 7∙32 | 8∙01 | 0∙69 | 6∙32 | 7∙01 | 0∙69 | 6∙76 | 7∙46 | 0∙70 | 6∙95 | 7∙71 | 0∙76 | 5∙50 | 6∙37 | 0∙87 | 7∙09 | 7∙76 | 0∙67 | 5∙77 | 6∙62 | 0∙85 |
| Costs\* | 11∙45 | 56∙85 | 45∙39 | 18∙05 | 55∙22 | 37∙17 | 8∙47 | 69∙57 | 61∙10 | 15∙01 | 49∙40 | 34∙39 | 57∙74 | 108∙22 | 50∙48 | 19∙49 | 51∙36 | 31∙87 | 11∙92 | 38∙01 | 26∙09 |
| ICER x USD (x GDPpc) | **66,032 (7∙24)** | | | **53,845 (27∙21)** | | | **87,200 (8∙14)** | | | **45,099 (3∙63)** | | | **58,283 (9∙34)** | | | **47,379 (8∙77)** | | | **30,610 (2∙63)** | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Scenario 3** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LYs | 9∙09 | 9∙97 | 0∙88 | 7∙87 | 8∙60 | 0∙73 | 8∙40 | 9∙21 | 0∙80 | 8∙63 | 9∙48 | 0∙85 | 6∙86 | 7∙51 | 0∙65 | 8∙80 | 9∙65 | 0∙84 | 7∙19 | 7∙88 | 0∙69 |
| QALYs | 7∙32 | 7∙85 | 0∙53 | 6∙32 | 6∙75 | 0∙43 | 6∙76 | 7∙23 | 0∙47 | 6∙95 | 7∙45 | 0∙50 | 5∙50 | 5∙87 | 0∙38 | 7∙09 | 7∙59 | 0∙50 | 5∙77 | 6∙17 | 0∙40 |
| Costs\* | 11∙45 | 56∙80 | 45∙35 | 18∙05 | 55∙15 | 37∙10 | 8∙47 | 69∙74 | 61∙28 | 15∙01 | 49∙29 | 34∙28 | 57∙74 | 109∙84 | 52∙10 | 19∙49 | 51∙39 | 31∙90 | 11∙92 | 37∙63 | 25∙70 |
| ICER x USD (x GDPpc) | **86,233 (9∙45)** | | | **86,684 (43∙80)** | | | **129,584 (12∙10)** | | | **68,226 (5∙49)** | | | **138,872 (22∙26)** | | | **63,803 (11∙81)** | | | **64,159 (5∙52)** | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Notes NT=No Trastuzumab arm; TZB=Trastuzumab arm; Diff=difference between the trastuzumab and the non-trastuzumab arms; LY= Life Years; QALYs= Quality Adjusted Life Years; ICER USD (x GDPPC)= incremental cost-effectiveness ratios expressed in United States dollars per QALY and in parenthesis expressed as gross domestic products per capita(GDPPC) per QALY Base case= absolute and relative risks from clinical trials; Scenario 1= alternative scenario one with country level absolute risks and trastuzumab relative risk from clinical trials; Scenario 2= alternative scenario two with country level absolute risks and adjusted trastuzumab relative risks Gross domestic products Argentina USD 9124, Bolivia USD 197, Brazil USD 10710, Chile USD 12431, Colombia USD 6240, Peru USD 5401, Uruguay USD 11633 (World Bank 2010) \*Costs are expressed in thousand dollars* | | | | | | | | | | | | | | | | | | | | | |